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Abstract. Mesothelioma, a highly aggressive cancer with 
poor prognosis and refractory to currently available therapies 
show increasing trends of its incidence in Japan and other 
developing countries. Although surgery is a gold standard for 
patients with early mesothelioma, most patients with advanced 
disease are not suitable for surgical resection and have option 
of palliative chemotherapy alone. One of the new treatment 
strategies for mesothelioma, the humanized anti-CD26 
monoclonal antibody therapy is under development. CD26, a 
110-kDa transmembrane glycoprotein with known dipeptidyl 
peptidase IV activity, plays a role in tumor development and its 
expression was reported in various human malignancies. This 
study determined the preliminary selection criteria for human-
ized monoclonal anti-CD26 antibody therapy. Eighty-one 
epithelioid (49 differentiated and 32 less differentiated), 34 
sarcomatoid, 19 biphasic mesothelioma and 8 mesothelioma 
cell lines were immunohistochemically examined using 8 
different commercially available anti-CD26 antibodies for 
membranous and cytoplasmic expression. The cytoplasmic 
expression of CD26 was observed in all histological types of 
mesothelioma, while the membranous expression of CD26 was 
found in 88% of differentiated and 69% of less differentiated 
epithelioid mesothelioma, and none of sarcomatoid meso-
thelioma with anti-CD26 antibodies with rabbit polyclonal 
anti-DPP4 antibody and similar results were also obtained 
with goat polyclonal anti-DPP4/CD26 antibody. These anti-
bodies absorbed with soluble human CD26 proteins do not 
show CD26 expression in mesothelioma tissue, suggesting 
these two antibodies localize true CD26 protein. Seven meso-
thelioma cell lines, including sarcomatoid types, also showed 
membranous expression of CD26 in cellblock preparation. 
CD26 vector transfection to CD26-negative MSTO-211H cells 
showed membranous expression of CD26 by flow cytometry, 
but not in tumor developed in NOD/SCID mice with inocula-
tion of CD26 vector transfected MSTO-211H cells. We found 
that both rabbit and goat polyclonal antibodies are suitable for 
immunohistochemical evaluation of membranous expression 
of CD26 in mesothelioma.
Introduction
Mesothelioma, primarily associated with exposure to asbestos, 
causes about 2,500 deaths per year in the United States alone 
(1). Although the incidence of mesothelioma has been reported 
as declining in the USA and Canada, a recent study still show 
a slight increase in death due to mesothelioma in USA (2) and 
its incidence is rising in Europe, Japan and other developing 
countries, causing more deaths. The data obtained from the 
‘Vital Statistics’ published by Ministry of Health, Labor and 
Welfare, Japan indicated that there is an increasing trend in 
the death due to mesothelioma, from 500 cases in 1995 to 
710 cases in 2000, and 911 cases in 2005 (3). It is a highly 
aggressive cancer with poor prognosis and refractory to 
currently available therapies (4,5). The conventional modali-
ties in management of mesothelioma by either surgery or 
radiotherapy and chemotherapy are not very effective, though 
some of the recent clinical trials of trimodality therapy with 
neoadjuvant chemotherapy followed by extra-pleural pneumo-
nectomy and radiotherapy have shown few months survival 
advantage over conventional therapy (6-8). In population-based 
studies, survival times ranged from 5 months to 13.2 months 
(9). Although surgery is an option for patients with early-stage 
mesothelioma, most patients present with advanced locally 
invasive disease, not amenable to surgical resection. For these 
patients, the current best treatment is palliative combination 
chemotherapy with cisplatin and pemetrexed. While this 
treatment regimen relieves symptoms and has been shown to 
confer a modest survival benefit (10), median survival is still 
only 9-12 months from diagnosis.
Therefore, the new treatment strategies for management of 
mesothelioma are an urgent need in the coming years. Various 
therapeutic monoclonal antibodies have emerged as new 
treatment modality in the treatment of cancers. Trastuzumab 
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targeting ErbB2 in breast cancer, cetuximab targeting EGFR 
or bevacizumab targeting VEGF in colorectal or lung cancers 
have already entered into standard clinical practice (reviewed 
in ref. 11). Humanized anti-CD26 monoclonal antibody having 
inhibitory effect on malignant mesothelioma cell growth 
in vitro and in vivo experiments has been reported (12), one 
of the a promising new developments for the antibody-based 
treatment of mesothelioma (12,13).
CD26 is a widely distributed 110-kDa transmembrane 
glycoprotein with known dipeptidyl peptidase IV activity in 
its extracellular domain (14,15). It is discovered as a lympho-
cyte cell surface antigen. It increases during T-cell activation 
as an essential role in the immune regulation and functions 
as a regulator of chemokine function. It has been reported to 
be expressed in various other tissues, placenta, kidney, lung, 
brain, liver, endothelium, and intestines (16-19). CD26 also 
plays a role in tumor development and its expression was 
reported in various human malignancies, mainly cancers of 
thyroid, breast, prostate, and ovary (13,20). We immunohisto-
chemically evaluated the expression of CD26 in mesothelioma 
in determining the proper selection criteria of the mesothe-
lioma patients for humanized monoclonal anti-CD26 antibody 
treatment.
Materials and methods
Tissue samples and mesothelioma cell lines. The formalin-
fixed paraffin-embedded (FFPE) tissue materials from 
mesothelioma cases were obtained from the tissue archives of 
the Department of Pathology, Hiroshima University. They were 
derived from patients who had undergone surgical resection 
or autopsy. The clinicoradiological data were retrieved from 
the hospital records. The microscopic slides were reviewed 
and reclassified using the current histological classification 
of tumors of lung and pleura, World Health Organization 
2004. Epithelioid mesothelioma was further sub-divided into 
two subtypes, i.e., ‘differentiated’ type (EM-D) and ‘less-
differentiated’ type (EM-LD) based on the morphology of 
‘papillo-tubular structures’ as an indicator of differentiation. 
Thus, EM-D were epithelioid mesothelioma showing papillo-
tubular pattern, micropapillary pattern, and/or microcystic 
pattern and EM-LD showing solid nest, trabecular pattern, 
signet-ring cell-like appearance and/or single cell infiltration 
pattern. One representative tissue block was used for immu-
nohistochemical confirmation of mesothelioma using positive 
and negative antibody panels mentioned in our previous publi-
cations (21-25). This study consisted of 81 cases of epithelioid 
mesothelioma (EM) (61%), 34 cases of sarcomatoid meso-
thelioma (SM) (25%) and 19 cases of biphasic mesothelioma 
(BM) (14%). The mean age of patients was 61.9 years (23-87 
years), and male/female ratio was 6:1. Forty-nine cases of 
epithelioid mesothelioma were differentiated type (EM-D) 
showing histological patterns of tubulopapillary, microcystic, 
or myxoid growth and 32 cases were less differentiated type 
(EM-LD) showing histological patterns of solid-sheet with 
polygonal, pleomorphic or bizarre giant cells. The study was 
carried out in accordance with the Ethical Guidelines for 
Human Genome/Gene Research of the Japanese Government.
Six epithelial type (epithelioid) and 2 fibroblastic type 
(sarcomatoid) mesothelioma cell lines were purchased either 
from Riken, Tokyo, Japan (ACC-MESO1, ACC-MESO4, 
HMMME) or American Type Culture Collection, Manassas, 
VA, USA (NCI-H226, NCI-H2452, MSTO-211H, NCI-H28, 
NCI-H2052). All mesothelioma cell lines were maintained 
in RPMI-1640 media with 10% fetal bovine serum, and 1% 
kanamycin, and 1% fungizone (all purchased from Gibco) at 
37˚C with 5% CO2.
Each of mesothelioma cell lines was cultured for 6-10 
days on laminin-coated wells of Lab-Tek II chamber slide 
system (Thermo Fisher Scientific, Tokyo, Japan) and 100 mm 
CellBind culture dish (Corning Life Sciences, Corning, NY). 
Cells in chamber slides were directly fixed with 10% buffered 
formalin for 10 min. Cells in culture dish were subjected to 
cell-block preparation using glucomannan (HoldGel 110, 
EBIS1 cell-block construction kit, Asia Kizai, Tokyo, Japan) 
according to the manufacturer's protocol.
CD 26 immunohistochemistry. CD 26 immunohistochem-
istry was performed in 3-µm-tissue sections prepared from 
formalin-fixed paraffin-embedded tissue blocks in APS-coated 
slides. Sections were deparaffinized by four changes of xylene, 
and rehydrated with graded series of ethanol. Endogenous 
peroxidase was inactivated by treatment with 0.3% H2O2 
in PBS for 30 min. The tissue sections were then incubated 
Table I. Source of antibodies.
Source/manufacturer Catalogue no. Host/clone Primary choice of application
Santa Cruz SC-9153 Rabbit/polyclonal WB, IP, IF, ELISA
MBL International DO68-1 Mouse (Clone 44-4) FC, IHC
Abcam Ab61825 Rabbit/polyclonal IHC-Paraffin
Lifespan Biosciences (MBL International) LS-A8060 Rabbit/polyclonal IHC-Paraffin
Acris Antibodies GmbH AP07044PU-N Rabbit/polyclonal IHC-Paraffin
Imgenex IMG72095 Rabbit/polyclonal IHC-Paraffin
Novus Biological NB100-59021 Rabbit/polyclonal IHC-Paraffin
R&D Systems AF1180 Goat/polyclonal WB, ELISA, IHC
WB, Western blotting; IP, immunoprecipitation; IF, immunofluorescence; ELISA, enzyme linked immunosorbent assay; FC, flow cytometry; 
IHC, immunohistochemistry.
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with commercially available anti-CD26/DPPIV antibodies 
purchased from various sources (Table I) at 4˚C overnight 
in a humidified chamber. The reaction was visualized using 
the Histofine Simple Stain kits (Nichirei Biosciences, Tokyo, 
Japan) and diaminobenzidine (Dojindo Laboratories, Tokyo, 
Japan) as the chromogen. The tissue sections were coun-
terstained for nucleus with Mayer's haematoxylin. Similar 
immunohistochemical procedure was carried out with the 
omission of the primary antibody as a negative control. CD26 
immunohistochemical procedure was also performed in 
mesothelioma cells on chamber slides and sections prepared 
from cell line blocks.
The membranous and cytoplasmic expression of CD26 was 
semi-quantitatively analyzed. The scoring system was based 
mainly on membranous staining: 0, no membranous staining 
of tumor cells; 1+, membrane staining in up to 25% of tumor 
cells; +2, membrane staining observed in 26-50% of tumor 
cells; +3, membrane staining in >50% of tumor cells.
Absorption study using soluble human CD26 proteins. 
Absorption study by soluble CD26 antigen was conducted 
to validate whether signal by immunohistochemistry using 
rabbit anti-human DPP4 polyclonal antibody (NB100-59021, 
Novus Biologicals, Littleton, CO, USA, hereafter we call as 
CD26-NB100/59021) or goat anti-human DPPIV/CD26 poly-
clonal antibody (AF1180, R&D Systems Inc., Minneapolis, 
MN, USA, hereafter we call as CD26-AF1180) corresponds 
to true CD26 localization or not. Two µg of rabbit anti-
human CD26-NB100/59021 or goat anti-human polyclonal 
antibody (CD26-AF1180) was incubated with 5 µg of recom-
binant soluble human CD26 proteins (produced by CHO cells, 
provided by Dr Kei Ohnuma, Tokyo University) overnight at 
4˚C. The solution was then centrifuged at 5,000 x g for 10 min 
and the pellet was discarded. The immunohistochemistry 
using this absorbed primary antibody as primary antibody was 
carried out as described above.
CD26 transfection into CD26-negative MSTO-211H mesothe-
lioma cells. MSTO-211H cells, which do not express CD26, 
were cultured as described above. MSTO-211H cells adhered 
to culture dish were transfected with a full-length CD26 
subcloned retroviral shuttle plasmid pLNCX2 vector (Clontech 
Inc., Mountain View, CA, USA) using the Lipofectin reagent 
(Invitrogen). Fresh media with 10% FBS was replenished 18 h 
after transfection and cells were harvested after 48 h.
The cells were stained with anti-human CD26 monoclonal 
antibody (BA5, Phycoerythrin-conjugated, diluted 1:100, 
Dako) for analysis with a flow cytometer (EPICS XL-MCL, 
Beckman Coulter, Hialeah, USA). Normal mouse IgG2a 
(Sigma-Aldrich) was used as a control.
Inoculation of MSTO-211H cells into NOD/SCID mice. All 
in vivo studies were approved by the Animal Care and Use 
Committee of Keio University. NOD/SCID mice were bred 
and maintained in Department of Pathology, Keio University. 
The human CD26 vector transfected-MSTO-211H cells were 
inoculated subcutaneously into the left flank of 6-week old 
female NOD/SCID mice. The resected subcutaneous tumor 
was fixed with 10% formalin and embedded in paraffin for 
immunohistochemical study.
Results
CD26 expression in mesothelioma tissue. The immunohisto-
chemical staining of CD26 expression was carried out with 
8 different commercially available antibodies against CD26/
DPP4. Using any of these antibodies, cytoplasmic expression of 
CD26 (cCD26) was observed in all mesothelioma cases (Fig. 1). 
Figure 1. CD26 expression in epithelioid mesothelioma with various antibodies. Cytoplasmic expression of CD26 is observed with all the 8 anti-CD26/DPP4 
antibodies studied. The membranous expression of CD26 is detected with only CD26-NB100/59021 and CD26-AF1180 antibodies.
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However, the membranous expression of CD26 (mCD26) could 
not be detected with SC-9153, DO-68, Ab61825, LS-A8060, 
AP01046PU-N, and IMG72095 antibodies. The membranous 
expression of CD26 in mesothelioma was only detected using 
either CD26-NB100/59021 or CD26-AF1180 antibodies.
CD26 expression was found in almost all cases of meso-
thelioma with membranous and/or cytoplasmic pattern using 
CD26-NB100/59021 or CD26-AF1180 antibody (Table II). 
The membranous expression patterns between these two 
antibodies were very similar (Fig. 1 and Table III). Using 
CD26-NB100/59021 antibody, the membranous expression of 
CD26 was found in 65 of 81 (80%) epithelioid mesotheliomas 
(Fig. 2, Table II), and 17 of 18 (89%) epithelioid component of 
biphasic mesothelioma. The membranous expression of CD26 
was not found in sarcomatoid mesothelioma or sarcomatoid 
component of biphasic mesothelioma (Fig. 2, Table II). Fifteen 
of 49 cases (31%) of EM-D showed mCD26 expression in >50% 
of tumor cells, 16 cases (33%) in 26-50% of tumor cells, and 
only 12 cases (25%) showed <25% of tumor cells (Table IV). 
Four of 32 cases (12%) of EM-LD showed mCD26 expression 
in >50% of tumor cells, 11 cases (34%) in 26-50% of tumor 
cells, and only 7 cases (22%) showed <25% of tumor cells 
(Table IV). Five of 18 cases (27%) of epithelioid component 
of BM showed mCD26 expression in >50% of tumor cells, 8 
cases (44%) in 26-50% of tumor cells, and only 4 cases (22%) 
showed <25% of tumor cells (Table IV).
CD26 expression in mesothelioma cell lines. Seven out of 8 
mesothelioma cell lines showed CD26 expression. MSTO-
211H mesothelioma cell line had no expression of CD26. The 
Table II. CD26 immunohistochemical score in mesothelioma.a
 CD26-NB100/59021 expression CD26-AF1180 expression
 ---------------------------------------------------------------------------------- -------------------------------------------------------------------------------------
  Score 0 Score 1 Score 2 Score 3 Score 0 Score 1 Score 2 Score 3
EM-D
 Cytoplasmic 0 3 12 34 0 2 12 35
 Membranous 6 12 16 15 6 16 19 8
EM-LD
 Cytoplasmic 0 2 11 19 0 0 15 17
 Membranous 10 7 11 4 10 7 12 3
BM-epithelioid component
 Cytoplasmic 0 1 8 9 0 1 6 11
 Membranous 1 4 8 5 4 6 6 2
BM-sarcomatoid component
 Cytoplasmic 0 3 15 0 0 4 13 1
 Membranous 18 0 0 0 18 0 0 0
Sarcomatoid mesothelioma
 Cytoplasmic 0 9 21 5 0 12 7 6
 Membranous 35 0 0 0 35 0 0 0
aDetailed data available online (http://home.hiroshima-u.ac.jp/byouri2/JP/Supple.html). EM-D, epithelioid mesothelioma-differentiated type; 
EM-LD, epithelioid mesothelioma-less differentiated type; BM, biphasic mesothelioma.
Table ΙΙΙ. Comparison of CD26 immunohistochemical score 
of CD26 expression with two antibodies.
 NB100-59021
 ----------------------------------------------------------------
  0 1+ 2+ 3+
AF1180 0 13 5 2 0
 1+ 4 14 10 1
 2+ 0 4 21 12
 3+ 0 0 2 11
p-value <0.0001.
Table IV. Immunohistochemical score of membranous CD26 
expression.
 Immunohistochemical score (%)
 -------------------------------------------------------------------------------------------------
 Total 0 1+ 2+ 3+
EM-D 49 6 (12.2) 12 (24.5) 16 (32.7) 15 (30.6)
EM-LD 32 10 (31.2) 7 (21.9) 11 (34.4) 4 (12.5)
BM (E) 18 1 (5.5) 4 (22.2) 8 (44.5) 5 (27.8)
EM-D, epithelioid mesothelioma differentiated type; EM-LD, epi-
thelioid mesothelioma-less differentiated type. BM (E), epithelioid 
component of biphasic mesothelioma.
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tumor cells derived from sarcomatoid mesothelioma when 
grown in chamber slides showed morphologically spindle-
shaped tumor cells (Fig. 3A), and had primarily cytoplasmic 
CD26 expression pattern with very few cells showing weak 
membranous expression (Fig. 3B). The cellblock prepara-
tions from the same mesothelioma cells, which transformed 
to round to oval cells due to trypsinization, showed promi-
nent cell membrane (Fig. 3C). In these preparations, mCD26 
expression was clearly evident (Fig. 3D).
Validation of polyclonal antibodies for true localization of 
CD26. Immunohistochemistry using either absorbed primary 
antibody of rabbit anti-human CD26 polyclonal antibody 
(CD26-NB100/59021) or goat anti-human CD26 polyclonal 
antibody (R&D, AF1180) showed disappearance of CD26 
expression in mesothelioma tissue (Fig. 4), suggesting these 
two antibodies localizes true CD26 protein.
CD26 expression after CD26 vector transfection into meso-
thelioma cells and tumor development in NOD/SCID mice. 
MSTO-211H cells, which primarily do not express CD26, 
showed membranous expression of CD26 after transfected 
with a full-length CD26 subcloned retroviral shuttle plasmid 
pLNCX2 vector by flow cytometric analysis (Fig. 5A).
NOD/SCID mice after inoculation of CD26 vector trans-
fected MSTO-211H cells developed mesothelioma. This tumor 
Figure 2. CD26 expression in mesothelioma using CD26-NB100/59021 antibody. Epithelioid mesothelioma differentiated type (A and B), shows membranous 
expression of CD26 and sarcomatoid mesothelioma (C and D) shows only cytoplasmic expression with inconspicuous membranous expression of 
CD26. (A and C) Hematoxylin eosin stain; (B and D) CD26 immunohistochemistry.
Figure 3. CD 26 expression in mesothelioma cell line. Mesothelioma cell line ACC-MESO-1, shows spindle cell growth in culture dish (A) and no membranous 
expression pattern of CD26 is detected (C). However, the cellblock preparation (B) from the same cell line shows membranous expression pattern of CD26 in 
tumor cells (D).
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showed cytoplasmic expression of CD26. No membranous 
expression of CD26 could be observed (Fig. 5B).
Discussion
Various unconjugated or immuno-conjugated monoclonal 
antibody-based therapies have been developed and already 
established as a new treatment modality in lymphomas, breast, 
lung, or colorectal cancers. Anti-CD20 antibody (rituximab) 
in lymphomas, anti-HER2 antibody (trastuzumab) in breast 
cancer, anti-EGFR antibody (cetuximab) or anti-VEGF (beva-
cizumab) in colorectal or lung cancers have entered standard 
clinical practice (reviewed in ref. 11). Other antibodies like 
MDX-010 humanized mAb (anti-CTLA-4 antibody), which 
inhibit T-cell activation, are also supposed to be promising 
(26). The possibility of humanized anti-CD26 monoclonal 
antibody treatment for its inhibitory effect has been reported 
on malignant mesothelioma cell lines in vitro and in vivo 
experiments (12). This is the new promising strategy in 
antibody-based treatment of mesothelioma (12,13).
The success of all antibody-based treatments of cancer 
largely depends on the proper selection of the cases. One such 
selection criterion is by the immunohistochemical expression 
in the tumor cells. For example, the selection of breast cancer 
patients for anti-HER2 antibody therapy depends upon the 
HER-2 expression in the tumor cells of those patients using 
immunohistochemical study. All breast cancers do not express 
HER-2 when analyzed by immunohistochemical staining 
alone and many cases do need further analysis of HER-2 
expression by fluorescence in situ hybridization (FISH). The 
interpretation manual has been developed for the management 
of such treatment (27). The same rule should be applied to 
humanized monoclonal CD26 antibody therapy to mesothe-
lioma and proper guidelines for selection of mesothelioma 
cases are required. We have, in this study, analyzed various 
commercially available antibodies to detect an antibody with 
reproducibility in correct interpretation of CD26 expression 
in the archived mesothelioma tissue and/or mesothelioma cell 
lines. Out of more than 50 different commercially available 
antibodies, we have selected the antibodies available in the 
past and newly developed antibodies available recently for 
immunohistochemical staining in FFPE sections. We found 
CD26-NB100/59021 antibody from Novus Biologicals or 
AF1180 from R&D systems are equally good for interpretation 
of membranous CD26 expression. We also validated these two 
antibodies for true localization of CD26 protein by absorption 
study using soluble human CD26 proteins.
The morphology of mesothelioma is generally found to 
be an important prognostic factor, epithelioid mesothelioma 
cases show better survival than sarcomatoid mesothelioma 
cases (28,29). In the present study, none of sarcomatoid meso-
thelioma expressed membranous CD26 in the tumor cells. The 
reason for this may be due to the morphological characteristics 
of sarcomatoid mesothelioma, primarily spindled shape. This 
can be better explained by our findings of CD26 expression 
in mesothelioma cell lines. The mesothelioma cells grow as 
spindled cells in culture medium with inconspicuous cell 
membrane. This can be even observed in some of the mesothe-
lioma cell lines derived from epithelioid mesothelioma cases. 
However, the same cells, when treated with trypsin, showed 
round to oval cells with distinct cell membrane. In this study, 
we found membranous CD26 expression in these mesothe-
lioma cells. In addition, the mesothelioma cells, when analyzed 
by flow cytometry to detect expression of cell surface antigen, 
clearly showed CD26 expression. On the other hand, it can also 
be postulated that the development of sarcomatoid mesothe-
lioma is by epithelial-mesenchymal transition from epithelioid 
mesothelioma. The concept of epithelial-mesenchymal transi-
tion was recognized at first as a central differentiation process 
in early embryogenic morphogenesis (30). The coordinated 
molecular and cellular changes defined as the reductions in 
Figure 4. Absorbed CD26 reactions after soluble CD26 antigens in immu-
nohistochemistry. The absorbed CD26 antibody is rabbit anti-human CD26 
polyclonal antibody (CD26-NB100/59021) was incubated with recombinant 
soluble human CD26 proteins produced by CHO cells. CD26 immunoreac-
tivity observed with anti-CD26 antibody (A) is not detected with absorbed 
CD26 antibody (B).
Figure 5. (A) CD26 vector-transfected MSTO-211H cells without fixation 
showing membranous expression of CD26 by flow cytometric analysis. Red 
curve, anti-CD26 antibody (phycoerythrin-conjugated monoclonal antibody, 
BA5); gray curve, control mouse IgG2a. (B) CD26 expression in human 
CD26 expression vector-transfered MSTO-211H cells. CD26 expression 
is mainly in the cytoplasm of mesothelioma developed after human CD26 
vector-transfected MSTO-211H cells were inoculated into NOD/SCID mice. 
(Immunohistochemistry with goat anti-human CD26 polyclonal antibody 
(CD26-AF1180).
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cell-cell adhesion, apical-basolateral polarity, and epithelial 
markers, as well as the acquisition of motility, spindle-cell 
shape, and mesenchymal markers. So, CD26 expression, 
which is prominent in epithelioid mesothelioma, more in 
differentiated type than less-differentiated type may have been 
lost after transition into the sarcomatoid mesothelioma, thus 
showing only cytoplasmic CD26 expression. Our CD26 vector 
transfected MSTO-211H cells, when inoculated to NOD/
SCID mice, show only cytoplasmic expression though surface 
antigen is clearly expressed in flow cytometric analysis. The 
detection of surface CD26 by flow cytometry can be another 
method of analyzing mCD26 expression in pleural fluid from 
mesthelioma patients.
In conclusion, we found overexpression of CD26 in mesothe-
lioma tissue and cell lines. By using NB100-59021 or AF1180 
antibody, immunohistochemical evaluation of membranous 
CD26 expression in human mesothelioma tissues is possible 
for selecting mesothelioma cases for humanized monoclonal 
anti-CD26 antibody treatment. Sarcomatoid mesothelioma 
in FFPE which do not show membranous CD26 expression, 
though existence of membranous expression in mesothelioma 
cell blocks suggest other method to evaluate CD26 expression 
such as flow cytometry is needed for selecting these cases for 
humanized monoclonal anti-CD26 antibody therapy.
Acknowledgements
The authors thank Ms. Yuka Fukushima for her excellent 
technical assistance, Ms. Keiko Honda and Naomi Fukuhara 
for official assistance. This research was supported by the 
program for promotion of fundamental studies in Health 
Sciences of the National Institute of Biomedical Innovation 
(C.M.).
References
  1. Weill H, Hughes JM and Churg AM: Changing trends in US 
mesothelioma incidence. Occup Environ Med 61: 438-441, 2004.
  2. Malignant mesothelioma mortality-United States, 1999-2005. 
MMWR Morb Mortal Wkly Rep 58: 393-396, 2009.
  3. Takeshima Y, Inai K, Amatya VJ, et al: Accuracy of pathological 
diagnosis of mesothelioma cases in Japan: clinicopathological 
analysis of 382 cases. Lung Cancer 66: 191-197, 2009.
  4. Pass HI, Vogelzang NJ, Hahn S and Carbone M: Malignant 
pleural mesothelioma. Curr Proble Cancer 28: 93-174, 2004.
  5. Robinson BW and Lake RA: Advances in malignant mesothe-
lioma. N Engl J Med 353: 1591-1603, 2005.
  6. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study 
of pemetrexed in combination with cisplatin versus cisplatin 
alone in patients with malignant pleural mesothelioma. J Clin 
Oncol 21: 2636-2644, 2003.
  7. Krug L, Pass H, Rusch V, et al: Multicenter phase II trial of 
neoadjuvant pemetrexed plus cisplatin dfollowed by extrapleural 
pneumonectomy and radiation for malignant pleural mesothe-
lioma. J Clin Oncol 18: 3007-3013, 2009.
  8. Weder W, Stahel R, Bernhard J, et al: Multicenter trial of neo- 
adjuvant chemotherapy followed by extrapleural pneumonectomy 
in malignant pleural mesothelioma. Ann Oncol 18: 1196-1202, 
2007.
  9. Montanaro F, Rosato R, Gangemi M, et al: Survival of pleural 
malignant mesothelioma in Italy: a population-based study. Int J 
Cancer 124: 201-207, 2009.
10. Marinaccio A, Montanaro F, Mastrantonio M, et al: Predictions 
of mortality from pleural mesothelioma in Italy: a model based 
on asbestos consumption figures supports results from age-
period-cohort models. Int J Cancer 115: 142-147, 2005.
11. Adams G and Weiner L: Monoclonal antibody therapy of cancer. 
Nat Biotechnol 23: 1147-1157, 2005.
12. Inamoto T, Yamada T, Ohnuma K, et al: Humanized anti-CD26 
monoclonal antibody as a treatment for malignant mesothelioma 
tumors. Clin Cancer Res 13: 4191-4200, 2007.
13. Thompson MA, Ohnuma K, Abe M, Morimoto C and Dang NH: 
CD26/dipeptidyl peptidase IV as a novel therapeutic target for 
cancer and immune disorders. Mini Rev Med Chem 7: 253-273, 
2007.
14. Torimoto Y, Dang N, Tanaka T, Prado C, Schlossman S and 
Morimoto C: Biochemical characterization of CD26 (dipep-
tidyl peptidase IV): functional comparison of distinct epitopes 
recognized by various anti-CD26 monoclonal antibodies. Mol 
Immunol 29: 183-192, 1992.
15. Morimoto C, Torimoto Y, Levinson G, et al: 1F7, a novel cell 
surface molecule, involved in helper function of CD4 cells. J 
Immunol 143: 3430-3439, 1989.
16. Abbott CA, Baker E, Sutherland GR and McCaughan GW: 
Genomic organization, exact localization, and tissue expres-
sion of the human CD26 (dipeptidyl peptidase IV) gene 
Immunogenetics 40: 331-338, 1994.
17. Morrison ME, Vijayasaradhi S, Engelstein D, Albino AP and 
Houghton AN: A marker for neoplastic progression of human 
melanocytes is a cell surface ectopeptidase. J Exp Med 177: 
1135-1143, 1993.
18. Stange T, Kettmann U and Holzhausen HJ: Immunoelectron 
microscopic demonstration of the membrane proteases amino-
peptidase N/CD13 and dipeptidyl peptidase IV/CD26 in normal 
and neoplastic renal parenchymal tissues and cells. Eur J 
Histochem 44: 157-164, 2000.
19. Su A, Wiltshire T, Batalov S, et al: A gene atlas of the mouse 
and human protein-encoding transcriptomes. Proc Natl Acad Sci 
USA 101: 6062-6067, 2004.
20. Havre P, Abe M, Urasaki Y, Ohnuma K, Morimoto C and 
Dang N: The role of CD26/dipeptidyl peptidase IV in cancer. 
Front Biosci 13: 1634-1645, 2008.
21. Kushitani K, Takeshima Y, Amatya VJ, Furonaka O, Sakatani A 
and Inai K: Immunohistochemical marker panels for distinguishing 
between epithelioid mesothelioma and lung adenocarcinoma. 
Pathol Int 57: 190-199, 2007.
22. Takeshima Y, Amatya VJ, Kushitani K and Inai K: A Useful 
antibody panel for differential diagnosis between peritoneal 
mesothelioma and ovarian serous carcinoma in Japanese cases. 
Am J Clin Pathol 130: 771-779, 2008.
23. Kushitani K, Takeshima Y, Amatya VJ, Furonaka O, Sakatani A 
and Inai K: Differential diagnosis of sarcomatoid mesothelioma 
from true sarcoma and sarcomatoid carcinoma using immuno-
histochemistry. Pathol Int 58: 75-83, 2008.
24. Takeshima Y, Amatya VJ, Kushitani K, Kaneko M and Inai K: 
Value of immunohistochemistry in the differential diagnosis 
of pleural sarcomatoid mesothelioma from lung sarcomatoid 
carcinoma. Histopathology 54: 667-676, 2009.
25. Amatya VJ, Takeshima Y, Kohno H, et al: Caveolin-1 is a novel 
immunohistochemical marker to differentiate epithelioid meso-
thelioma from lung adenocarcinoma. Histopathology 55: 10-19, 
2009.
26. Sanderson K, Scotland R, Lee P, et al: Autoimmunity in a phase 
I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 
monoclonal antibody with multiple melanoma peptides and 
Montanide ISA 51 for patients with resected stages III and IV 
melanoma. J Clin Oncol 23: 741-750, 2005.
27. Wolff A, Hammond M, Schwartz J, et al: American Society of 
Clinical Oncology/College of American Pathologists guideline 
recommendations for human epidermal growth factor receptor 
2 testing in breast cancer. Arch Pathol Lab Med 131: 18-43, 
2007.
28. Edwards J, Abrams K, Leverment J, Spyt T, Waller D and 
O'Byrne K: Prognostic factors for malignant mesothelioma 
in 142 patients: validation of CALGB and EORTC prognostic 
scoring systems. Thorax 55: 731-735, 2000.
29. Antman K, Shemin R, Ryan L, et al: Malignant mesothelioma: 
prognostic variables in a registry of 180 patients, the Dana-
Farber Cancer Institute and Brigham and Women's Hospital 
experience over two decades, 1965-1985. J Clin Oncol 6: 
147-153, 1988.
30. Shook D and Keller R: Mechanisms, mechanics and function of 
epithelial-mesenchymal transitions in early development. Mech 
Dev 120: 1351-1383, 2003.
